Patent Application
20250230430
The present application claims the benefit of priority for Chinese Patent Application No. 202210303736.0 filed on Mar. 24, 2022, the content of which is incorporated herein by reference in their entirety.
The present disclosure belongs to the field of molecular biology, particularly to the technical field of gene analysis and detection, and specifically relates to a method for preparing a DNA library and a method for detecting a retroviral integration site. In particular, the present disclosure relates to a method for absolute quantitative detection of a retroviral (e.g., lentiviral) integration site.
Gene and cell therapy is an effective means of treating genetic diseases and other malignant diseases, for example, CD19 and BCMA CAR-T have been approved for clinical use in the treatment of hematological tumors. Currently, CAR-T products marketed worldwide use viral vector transduction, such as Kymriah from Novartis, which is developed and produced on the basis of a lentiviral vector, and Yescarta from Kite/Gilead, which uses a γ-retroviral vector transduction system.
According to the current international virus taxonomy criteria, the Retroviridae family is divided into 7 genera: Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus and Spumavirus, wherein the Lentivirus is subdivided into 5 groups, including bovine lentivirus group, equine lentivirus group, feline lentivirus group, ovine lentivirus group, and human lentivirus group. HIV is defined in the “large family” of viruses as belonging to the human immunodeficiency virus group in the genus Lentivirus of the Retroviridae family.
Lentiviruses, a subset of retroviruses, are one of the most common and useful types of viruses in research. Lentiviruses can transduce dividing and non-dividing cells without producing an obvious immune response. These viruses can also be stably integrated into a host genome, thereby enabling long-term transgene expression. There are some safety considerations that need to be assessed when using lentiviruses: these viruses are HIV-1-based and may require additional laboratory biosafety procedures. In addition, these viruses may inactivate tumor suppressor genes or activate proto-oncogene expression due to their random integration into the host genome, leading to the risk of carcinogenesis (Hacein-Bey-Abina S et al., science, 2003, 302 (5644): 415-419; Six E et al., Molecular Therapy. 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA: CELL PRESS, 2017, 25 (5): 347-348; Bluebird bio reports second quarter financial results and provides operational update. News release. bluebirdbio. Aug. 9, 2021).
γ-retrovirus is an RNA virus consisting of its genome and several structural proteins and enzymatic proteins, including reverse transcriptases and integrases. Once entering the target cell, the virus uses two reverse transcriptases to produce a DNA provirus. This provirus is then integrated into the host genome by accompanying integrase proteins.
When scientists discuss retroviruses, they usually refer to a subset of retroviruses, called γ-retroviruses. γ-retroviruses can encapsulate relatively large amounts of DNA (up to 8 kb), and infection results in long-term transgene expression. Some disadvantages of γ-retroviruses are that they only transduce dividing cells (because they can enter the nucleus only upon nuclear envelope breakdown during mitosis). In addition, γ-retroviruses are randomly integrated into the host genome, which may lead to tumorigenesis (referred to as insertion mutation).
In preclinical studies and clinical applications, the assessment of viral integration sites and associated safety is a must. For example, both the US FDA and the European EMA require the detection of viral integration sites and integration frequency in gene and cell therapy to clarify the safety of this therapy (O'Leary M C et al., Clinical Cancer Research, 2019, 25 (4): 1142-1146; U.S. Department of Health and Human Services. Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry. Jan. 30, 2020; European medicines agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 22 March, 2018). The domestic “Technical Guidelines for Non-clinical Research of Genetically Modified Cell Therapy Products (Trial)” (November 2021) also clarifies the risk assessment of integration/insertion sites as part of the preclinical safety evaluation.
In addition, the detection technology of viral integration sites can also be used to track the clonal evolution of engineered immune cells after cell therapy. Compared to the detection method of using CAR-T-specific TCR (CAR-T therapy) to track the proportion of CAR-T cells, the method for detecting viral integration sites has the following advantages: 1) no need to identify and distinguish specific TCR sequences for CAR-T and endogenous T cells prior to tracking at serial time points; 2) no need to sort CAR-T in samples; 3) no need for fresh blood/tissue samples; and 4) low cost, short experimental period, etc.
At present, there are several methods for detecting viral integration sites: 1) probe method, which is relatively low in sensitivity and difficult to implement in samples with low integration ratio; 2) linear amplification-mediated (LAM)-PCR, on which the existing analyses of viral integration sites are mostly based; 3) modified genome sequencing (MGS)-PCR, which has a relatively simpler process compared to LAM-PCR; and 4) amplicon method, a combination of LAM-PCR using non-restriction endonuclease cleavage and anchored multiplex PCR, which can be used for the detection of lentiviral integration sites.
However, the above-mentioned methods all have some drawbacks, such as low sensitivity and poor accuracy. In addition, none of the above-mentioned methods can achieve absolute quantification of each integration site, and the sensitivity of the method cannot be assessed when the overall copy number is unknown. Therefore, there is still a need to develop new methods for detecting retroviral integration sites.
The inventors, through intensive research and inventive efforts, have obtained a method for preparing a DNA library and the prepared DNA library and have further obtained a method for detecting a retroviral integration site. The inventors have surprisingly found that the detection method of the present disclosure has extremely high sensitivity, thus having good application potential. The following invention is thus provided:
One aspect of the present disclosure relates to a method for preparing a DNA library, comprising the steps of:
Without being bound by theory, the reaction system in which an internal reference gene is incorporated will enable the formation of a sufficient amount of DNA even when the content/frequency of integration sites in samples is particularly low (for example, 1% or less) to complete the detection with a stable reaction program. The inventors have found that, when PCR is used to amplify and enrich integration sites, in the case where the content/frequency of integration sites in samples is particularly low, if no internal reference gene is introduced, a sufficient amount of DNA for purification and use as a template for the next PCR cannot be obtained under a fixed number of PCR cycles, which will make the detection step impossible. In this case, there are usually two solutions: 1. to obtain a sufficient amount of DNA, amplification is performed at high cycle numbers, but this results in an increase in non-specific amplification, affecting the effective data and quality of the final library; 2. other methods are used to predict the total frequency of integration sites and flexibly adjust the number of cycles to complete library construction, but at this time, the library construction procedure using each batch of data is inconsistent, resulting in inconsistent library quality and impossible establishment of stable background filtering thresholds for downstream data analysis.
Without being bound by theory, the sequencing read of the internal reference gene can be used as a standard for downsample (downsample, random extraction of narrowed data) for subsequent bioinformatics analysis to ensure that the depth of sequencing for each integration site remains consistent in each experiment. When downsample of data is performed according to a certain amount of the internal reference gene, the depth of sequencing can remain as consistent as possible regardless of the number of copies of integration sites, so that a stale cutoff value (for example, 3 reads or more detected is determined to be a true result) can be used to filter background noise in each experiment. In the absence of an internal reference gene, since the frequency of integration sites in each sample is inconsistent, the actual depth of sequencing for each integration site is inconsistent in different samples when downsample is performed according to a certain amount of sequencing data, which will cause the magnitude of the background noise to be different in different samples, and therefore it is impossible to form a stable cutoff value to remove background noise.
In addition, the internal reference gene of the present disclosure can be used as a calibration value to calibrate the concentration of copy number (copy number/μg gDNA) in a sample for each integration site in the sample of the present disclosure, thereby enabling absolute quantification of each integration site.
In some embodiments of the present disclosure, in the preparation method, the retrovirus-infected cell is an engineered immune cell, and the engineered immune cell comprises a chimeric antigen receptor; preferably, the engineered immune cell is selected from a cytotoxic T cell, a helper T cell, a natural killer T cell, a γδ T cell, an NK cell, a macrophage, a B cell, an antigen presenting cell, a dendritic cell and a stem cell-induced immune cell.
In some embodiments of the present disclosure, in the preparation method, in step 1), the DNA fragment is 500-1500 bp, 800-1200 bp, 900-1100 bp or 1000 bp in length.
In some embodiments of the present disclosure, in the preparation method, in step 2), the fixed sequence is 14-30 bases in length; and/or
The random UMI sequence is formally (N)x, in which N independently represents base A, G, C or T, x is a natural number of 5-12 or 5-9, such as 5, 6, 7, 8, 9, 10, 11 or 12.
In some embodiments of the present disclosure, in the preparation method, in step 2), the 5′ end of the short-strand sequence is provided with a modification that prevents primer extension, preferably an inverted dT modification or a dideoxycytidine modification.
In some embodiments of the present disclosure, in the preparation method, in step 4), the primers for the LTR sequence in the second round of PCR are located downstream of the primers for the LTR sequence in the first round of PCR,
In some embodiments of the present disclosure, in the preparation method, the total number of cycles in the first round of PCR, the second round of PCR and the third round of PCR is 36-63, preferably 36-45 or 38-42.
In some embodiments of the present disclosure, in the preparation method, the ratio of the number of cycles in the first round of PCR to that in the second round of PCR is (1-3): 2, for example, 1:2, 3:2, 1:1 or 3:4;
In some embodiments of the present disclosure, in the preparation method, the number of cycles in the third round of PCR is 6-13, for example, 6, 10 or 13;
In some embodiments of the present disclosure, in the preparation method,
In some embodiments of the present disclosure, in the preparation method,
In some embodiments of the present disclosure, in the preparation method, the first round of PCR products, the second round of PCR products and/or the third round of PCR products having a fragment length of less than 1000 bp are obtained by magnetic bead screening.
In some embodiments of the present disclosure, in the preparation method, the internal reference gene is a house-keeping gene, for example, gene ATCB, gene GAPDH or gene ApoB.
In some embodiments of the present disclosure, in the preparation method, the retrovirus is a lentivirus or a γ-retrovirus.
Another aspect of the present disclosure relates to a DNA library prepared by the preparation method of any one in the present disclosure; wherein preferably, the DNA library is a sequencing library; more preferably, the DNA library is a sequencing library for detecting a retroviral integration site.
A still further aspect of the present disclosure relates to a method for detecting a retroviral integration site, comprising the steps of sequencing the DNA library of the present disclosure and obtaining sequencing data;
A still further aspect of the present disclosure relates to a method for detecting a retroviral integration site, comprising the method for preparing a DNA library of any one in the present disclosure, and further comprising the step of:
In some embodiments of the present disclosure, the detection method further comprises the step of:
In some embodiments of the present disclosure, the process of bioinformatics analysis is as shown in
In the bioinformatics analysis process of the present disclosure, a cutoff value is set to filter ultra-low frequency fragments, and the cutoff value is adjusted so that the detection results after background removal are as consistent as possible with the theoretical values/values verified by other methods such as ddPCR. False positive fragments due to PCR or sequencing errors are effectively reduced; downsample is performed on the sequencing data so that the depth of sequencing for an internal reference gene and integration site fragments remains consistent; and UMI deduplication is used to reduce the result differences caused by different fragment amplification efficiencies.
In some embodiments of the present disclosure, the detection method is a quantitative detection method, preferably an absolute quantitative detection method.
In some embodiments of the present disclosure, in the detection method, the retrovirus is a lentivirus or a γ-retrovirus.
In some embodiments of the present disclosure, the process of the detection method is as shown in
In a particular embodiment of the present disclosure, the general process of the method for absolute quantitative detection of a retroviral integration site is as follows:
On the basis of conforming to common knowledge in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain various embodiments of the present disclosure.
Reagents and raw materials used in the present disclosure are all commercially available.
A still further aspect of the present disclosure relates to a method for preparing an engineered immune cell, comprising the step of detecting the engineered immune cell according to the detection method of any one in the present disclosure.
In some embodiments of the present disclosure, further comprised are identifying the integration sites and/or integration frequencies of retroviruses (e.g., lentiviruses or γ-retroviruses), analyzing the characteristics of genomic alterations, assessing the safety associated with lentiviral integration sites, and assessing potential risks. By means of assessment, engineered immune cells that have a low probability or no probability of developing abnormal cell behavior (for example, causing a mutation in a key gene or activating a proto-oncogene, which in turn leads to an increased risk of developing a malignant tumor) and meet relevant safety criteria can be released for subsequent scale-up culture, preservation or combination with a pharmaceutically acceptable carrier to obtain a pharmaceutical composition, etc.
In some embodiments of the present disclosure, in the method for preparing an engineered immune cell, the engineered immune cell is obtained by a method comprising the steps of:
In particular, the method for preparing an engineered immune cell may comprises transfecting or transducing immune cells isolated from an individual such that the immune cells express desired CAR(s). Methods for preparing engineered immune cells for immunotherapy are described in, for example, WO 2014/130635, WO 2013/176916 and WO 2013/176915, which are incorporated herein by reference. Individual steps that can be used to prepare engineered immune cells are disclosed in, for example, WO 2014/039523, WO 2014/184741, WO 2014/191128, WO 2014/184744 and WO 2014/184143, which are incorporated herein by reference.
For example, provided is a method for preparing an engineered immune cell, comprising the steps of isolating an immune cell, preparing a retroviral vector encoding a CAR (chimeric antigen receptor), introducing the vector into the immune cell, etc. to obtain the engineered immune cell. The obtained engineered immune cell is subjected to the step of performing absolute quantitative detection of a retroviral integration site of any one in the present disclosure, thereby assessing whether the engineered immune cells prepared achieve the desired effect without potential safety risks. As a result, the engineered immune cells that meet the expected requirements are obtained.
In some embodiments of the present disclosure, in the method for preparing an engineered immune cell, the engineered immune cell is selected from a cytotoxic T cell, a helper T cell, a natural killer T cell, a γδ T cell, an NK cell, a macrophage, a B cell, an antigen presenting cell, a dendritic cell and a stem cell-induced immune cell.
In a particular embodiment of the present disclosure, the engineered immune cell is a CAR-T cell.
The present disclosure also relates to any one or more of items 1 to 13 selected from:
The present disclosure achieves any one or more of the following technical effects (1) to (8):
The present disclosure is further described below by way of examples; however, the present disclosure is not limited to the scope of the described examples. For the experimental methods in which no specific conditions are specified in the following examples, selections are made according to conventional methods and conditions or according to the product instructions.
The test cell line gDNA for the detection of lentiviral integration sites in the present disclosure is derived from a CAR-T positive single copy cell line independently prepared and preserved in our company with a positivity rate close to 100%, verified by qPCR and ddPCR, and stored at −20 degrees Celsius (° C.). CAR-T cells are themselves a source of genomic DNA, so the present disclosure is not limited to the above-mentioned cell line, and any cell from which DNA can be obtained is applicable.
The genomic DNA used in the present disclosure is derived from CART cells, but the DNA used in the method is not limited to DNA derived from CART cells. For example, the DNA can also be the international standard WHO 1st Reference Reagent 2019 for lentiviral vector integration site analysis, available from: https://www.nibsc.org/products/brm_product_catalogue/detail_page.aspx?catid=18/144.
The test cell line gDNA for the detection of retroviral integration sites in the present disclosure is derived from two independently prepared and preserved monoclonal cell lines (cell lines 1 and 2) in our company which are isolated after γ-retrovirus transfection, and verified by ddPCR. The present disclosure is not limited to the above cell lines, and any cell from which DNA can be obtained is applicable.
1.1 300 to 1000 ng of genomic DNA was taken, diluted to a total volume of 130 μL using Ultrapure water, and mixed uniformly.
1.2 130 μL of the resulting solution was all added into a microTUBE AFA Fiber Snap-Cap tube.
1.3 The following program was run on a Covaris M220 to sonicate the genomic DNA:
1.4 After the sonication was completed, the sonicated products were immediately transferred to an EP tube for the next step.
1.5 To the sonicated products in the previous step were added 230 μL of (1.8×) SPRIselect beads, then the resulting mixture was mixed uniformly using a pipette, and incubated for 5 min at room temperature.
1.6 The EP tube was transferred to a magnetic stand. After the liquid was clear, 350 μL of the liquid was aspirated and discarded.
1.7 300 μL of 80% (v/v) ethanol was added, and after 30 s, the supernatant was carefully removed.
1.8 200 μL of 80% ethanol was added, and after 30 s, the supernatant was carefully removed.
1.9 The EP tube was centrifuged, and then transferred to the magnetic stand, and the residual liquid was aspirated.
1.10 Drying was performed for 2 min at room temperature, the EP tube was removed from the magnetic stand, and 50.5 μL of EB buffer was immediately added to resuspend the magnetic beads.
1.11 Incubation was performed for 5 min at room temperature, and 50 μL of the product was transferred into a PCR tube.
To 50 μL of the product was added 15 μL of End Prep Mix 4 (Vazyme N203-02), then the resulting mixture was mixed uniformly, centrifuged, and placed in a PCR instrument, and the following program was run:
2.2 SPRIselect beads were shaken until completely resuspended.
2.3 52 μL of SPRIselect beads (0.8×) were added to 65 μL of each sample, uniformly mixed by pipetting 15 times using a tip, and incubated for 5 min at room temperature.
2.4 The PCR tube was placed on a magnetic stand until the supernatant was clear and transparent, and the supernatant was carefully removed and discarded.
2.5 200 μL of 80% ethanol was added, and after 30 s, the supernatant was carefully removed.
2.6 200 μL of 80% ethanol was added, and after 30 s, the supernatant was carefully removed.
2.7 The PCR tube was centrifuged, and transferred to the magnetic stand, and the residual liquid was aspirated.
2.8 Drying was performed for 2 min at room temperature, the EP tube was removed from the magnetic stand, and 21 μL of 1×IDTE Buffer (IDT, 11-05-01-09) was immediately added to resuspend the magnetic beads.
2.9 Incubation was performed for 5 min at room temperature, and 20 μL of the product was transferred into a PCR tube.
3.1 DNA oligo to be annealed was formulated with NFW (Nuclease-Free Water) to a solution with a final concentration of 50 μM. Annealing Buffer for DNA Oligos (5×) (Beyotime D0251) was dissolved and mixed uniformly for later use.
3.2 The information of the specific adapters used is as shown in Table 16.
3.3 An annealing system was set up as follows:
3.4 The following program was run on an ABI proflex PCR system instrument:
4.1 2× Rapid Ligation buffer and T4 DNA ligase (Vazyme N103) were thawed, then uniformly mixed by inverting, and put on ice for later use. The ligation reaction system was formulated according to the following table:
4.2 The system was uniformly mixed using a pipette, and centrifuged for a short time, the above-mentioned mixed system was placed in an ABI proflex PCR system instrument, and the program as shown in the following table was run:
4.3 SPRIselect beads were shaken for uniformly mixing, and completely and uniformly mixed using a pipette.
4.4 48 μL of SPRIselect beads (0.8×) were pipetted into the ligation product, completely and uniformly mixed using a pipette, and incubated for 5 min at room temperature.
4.5 The EP tube was transferred to a magnetic stand. After the liquid was clear, the supernatant was carefully removed and discarded.
4.6 200 μL of 80% ethanol was added, and after 30 s, the supernatant was carefully removed.
4.7 200 μL of 80% ethanol was added, and after 30 s, the supernatant was carefully removed.
4.8 The PCR tube was centrifuged, and transferred to the magnetic stand, and the residual liquid was aspirated.
4.9 Drying was performed for 2 min at room temperature, the EP tube was removed from the magnetic stand, and 21 μL of 1×IDTE Buffer was immediately added for resuspension.
4.10 Incubation was performed for 5 min at room temperature, and 20 μL of the product was transferred into a new PCR tube.
5.1 The components in the Phanta Super-Fidelity DNA Polymerase (Vazyme P501) kit were thawed and then completely shaken, wherein all operations should be performed on ice.
5.2 The first round PCR reaction system was formulated as follows:
The information of the primers used in this step is as shown in Table 16 below.
5.3 The system was pipetted using a pipette, and centrifuged for a short time, the above-mentioned mixed system was placed in an ABI proflex PCR system instrument, and the program as shown in the following table was run:
5.4 SPRIselect beads were shaken until completely resuspended.
5.5 30 μL of SPRIselect beads (0.6×) were pipetted into each sample, uniformly mixed by pipetting 15 times using a tip, and incubated for 5 min at room temperature.
5.6 The PCR tube was placed on a magnetic stand until the supernatant was clear and transparent, and then the supernatant was transferred to a new PCR tube.
5.7 10 μL of SPRIselect beads (0.8×) were added to each sample, uniformly mixed by pipetting 15 times using a tip, and incubated for 5 min at room temperature.
5.8 The PCR tube was placed on a magnetic stand until the supernatant was clear and transparent, and the supernatant was carefully removed.
5.9 200 μL of 80% ethanol was pipetted into each tube, and let to stand for 30 s, and the ethanol liquid was carefully removed and discarded.
5.10 200 μL of 80% ethanol was pipetted into each tube, and let to stand for 30 s, and the ethanol liquid was carefully removed and discarded.
5.11 The PCR tube was centrifuged instantaneously, and was placed on the magnetic stand, the residual ethanol was removed and discarded, and drying was performed for 2 min at room temperature.
5.12 The PCR tube was taken from the magnetic stand, 21 μL of 1×IDTE Buffer was added and uniformly mixed by pipetting 15 times using a tip, and incubated for 2 min at room temperature.
5.13 The PCR tube was placed on a magnetic stand until the supernatant was clear and transparent.
5.14 20 μL of the sample was transferred into a new tube, and the sample was stored at 4° C. for 72 h or at −20° C. for a long period of time, or directly used for the next experiment.
6.1 The components in the kit were thawed and then completely shaken, wherein all operations should be performed on ice.
6.2 The second round PCR reaction system was formulated as follows:
6.3 The information of the primers used in this step is as shown in Table 16 below.
6.4 The system was pipetted using a pipette, and centrifuged for a short time, the above-mentioned mixed system was placed in an ABI proflex PCR system instrument, and the program as shown in the following table was run:
6.5 Steps 5.4-5.14 were repeated.
7.1 The components in the kit were thawed and then completely shaken, wherein all operations should be performed on ice.
7.2 The third round PCR reaction system was formulated as follows:
The information of the primers used in this step is as shown in Table 16 below.
7.3 The system was pipetted using a pipette, and centrifuged for a short time, the above-mentioned mixed system was placed in an ABI proflex PCR system instrument, and the program as shown in the following table was run:
7.4 Steps 5.4-5.13 were repeated.
7.5 20 μL of the sample was transferred into a new tube. The concentration of the purified product was detected using Qubit, and the size of fragments was detected using Tapestation 4150. The library can subsequently be put directly into Illumina sequencer for sequencing.
The data analysis process involved in the present method is as follows:
Inverted dT modifications on the short strand of the adapter can avoid or reduce non-specific amplification in the PCR reaction. According to the experimental methods described in the present disclosure, ligation and repair were performed on the sonicated DNA using adapters with inverted dT and adapters without inverted dT, respectively, the first round of PCR was then performed, followed by the purification using 0.8× magnetic beads, then the second round of PCR was performed, and the fragment size and distribution analysis were performed on the samples in the constructed library using Tapestation 4150 automated electrophoresis instrument. The results are as shown in
The number of amplification cycles was minimized, thereby effectively reducing the soft-clip ratio and base deviations generated by amplification. By adjusting the number of cycles in each of the three rounds of PCR, the soft-clip ratio was counted after extracting the reads of the target gene by the bioinformatics analysis process of the present disclosure as described above. The results show that the soft-clip ratio decreases as the total number of cycles decreases, as shown in
By introducing the primer set of internal reference gene hApoB while determining the lentiviral integration site, the amount of the sonicated fragments introduced can be obtained from the internal reference gene so as to achieve the absolute quantification of the copy number of each integration site and determination of the sensitivity of the method.
Using this method, cell lines with known insertion sites that were gradiently diluted were detected. The results are as shown in Table 13 and
The bioinformatics analysis was performed for further optimization, wherein background noise was effectively filtered by setting cutoff values. Taking 20211125-4-lib as an example, 10 ng of Jurkat clone10 P32 (a single copy cell line verified by ddPCR, with a copy number of LTR:ApoB=1:2) and 990 ng of normal human PBMC were selected to prepare a simulation sample at a mass ratio of 1%, that is, the theoretical copy number ratio of LTR:ApoB was 0.5%. The initial molecules in the original bam alignment file were counted by library construction, sequencing and analysis using the method as described above, the median was calculated for the number of initial molecules, and the reads counts corresponding to the initial molecules which was less than 1% of the median was set as background. The plot is as follows (
UMI deduplication is set to effectively reduce fragment amplification errors and differences in amplification efficiency of different fragments caused during PCR. Statistics on the distribution of reads counts for the initial molecules of the target gene in 20211125-4-lib was performed (such as
With the above optimization, the method of the present disclosure can detect integration sites with single site copy numbers greater than or equal to more than 17 copies/μg gDNA in a sample, while maintaining good linearity above 107 copies/μg gDNA (Table 14). It can therefore be truly applied in the follow-up detection of clinical samples of genetically modified cell therapy based on lentiviral transfection technology. The following are examples of applications where all detection sites can be verified by ddPCR with 100% accuracy after the detection on different cell lines using the present method. The results are as shown in Table 15.
NNNNNACACTCTTTCCCTACACGAC
In addition to being applicable to the detection of integration sites of lentiviruses (or vectors), the inventors have changed the primers in the first and second rounds to be specific primers for the LTR of γ-retroviruses (such as MSCV/MoMLV), demonstrating that the method is equally applicable to the detection of integration sites of γ-retroviruses (or vectors).
Using the library construction and analysis process of the present patent, primers in the first and second rounds were changed to be specific primers (Rvbd_F_1_3 and Rvbd_F_2_3 in Table 20) for the LTR of γ-retrovirus, and two monoclonal cell lines (cell lines 1 and 2) isolated after retrovirus transfection were subjected to RIS library construction and analysis to obtain integration site information, combinations of specific primers/probes were set according to the integration site information, and verification was performed by ddPCR. The results are as shown below:
As can be seen from the comparison between the results detected by NGS and the results detected by ddPCR, the negative conformity rate and the positive conformity rate obtained using the NGS detection process of the present patent are both 100%, that is, the method can specifically detect RIS sites, with ddPCR as a reference.
Cell line 1 and cell line 2 were mixed at different ratios, wherein the DNA of cell line 2, as background DNA, was mixed with 1% and 0.1% of the DNA of cell line 1, respectively, and similarly, the DNA of cell line 1, as background DNA, was mixed with 1% and 0.1% of the DNA of cell line 2, so as to prepare sensitivity samples 1, 2, 3 and 4, RIS library construction was performed, bioinformatics analysis was performed after sequencing to obtain the information of the proportion of RIS sites, and the obtained information was compared with theoretical values. The results are as shown in the table below:
The results show that the detection rate is 100% (10/10) when the sensitivity (RIS/ALL) of the present method is at a theoretical ratio of 0.167% to 0.249%, and the detection rate is 90% (9/10) when the sensitivity of the present method is at a theoretical ratio of 0.0167% to 0.025%. The sensitivity (RIS/ALL) of the present method was preliminarily determined to be below 0.167%.
It can be foreseen from the above examples that for the integration sites of viral/non-viral vectors for genomic integration on the basis of fixed integration sequences (such as long terminal repeats (LTRs) of retroviruses and inverted terminal repeats (ITRs) of adeno-associated viruses), the detection of integration sites of a variety of viral/non-viral vectors can be realized in conjunction with the method of the present disclosure by designing specific primers for this fixed integration sequence.
Although the specific embodiments of the present disclosure have been described in detail, it will be understood by a person skilled in the art that: according to all the teachings disclosed, various modifications and replacements can be made to those details, and these changes are within the scope of the protection of the present disclosure. The full scope of the present disclosure is given by the appended claims and any equivalents thereof.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202210303736.0 | Mar 2022 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2023/083705 | 3/24/2023 | WO |
